But it did not explain why ~5% of individuals (adults) unvaccinated still remain asymptomatic after SARS-CoV-2 infection.
This is an important question. Identifying genetic variants may help identify drug targets.
In July 2023, a study showed that a common HLA allele, HLA-B*15:01 was associated with asymptomatic SARS-CoV-2 infection.
Mechanism ?
Prior infections with seasonal coronaviruses (common cold) may protect those with HLA_B*15:01 against SARS-CoV-2nature.com/articles/s4158…
It would make sense immunologically if seasonal coronavirus-specific and HLA-restricted T cells cross react with SARS-CoV-2 antigens presented by the same molecules.
We therefore tested the hypothesis that HLA alleles are associated with silent SARS-CoV-2 infection
We studied 3 diverse cohorts:
- A prospective cohort from USA where participants self-reported symptoms. @my_helix & Healthy Nevada Project
- A large international consortium where physicians refer patients
- the UK SARS-CoV-2 Human Challenge Studycovidhge.com
Study design
The hardest part was how to define asymptomatic, especially for the US prospective cohort. See next tweet.
Overall we did 3 HLA-WAS for each cohort. And then 3 meta-analyses.
Asymptomatic should be: no symptoms at all. Easy.
Issue is N.
So we considered 2 other definitions:
- allowing 1 symptom for 1 day.
- allowed symptoms that lasted ≤2 days (similar to what they did in the B*1501 paper, see their Figure S10).
In the US prospective cohort, we used HIBAG to call HLA alleles in 7 genes.
We tested 105 alleles for association, those present in at least 1% of our cohort.
There were no association between any HLA allele and asymptomatic SARS-CoV-2 (using any of the 3 definitions) in the US prospective cohort.
Similarly, there was no association between any HLA allele and asymptomatic SARS-CoV-2 in the COVID HGE cohort.
This analysis was led by Astrid Marchal and @AurelieCobat
Doing the meta-analysis did not identify any statistically significant associations either.
This includes B*15:01. We did not find any association, and no enrichment at all, of B*15:01 allele in the asymptomatic groups in any of the 2 cohorts.
I was surprised by this result because the US prospective cohort in our study is similar to the cohort in the @Nature study:
- from US
- volunteers
- self-reported data (same symptoms assessed)
- more women
and we had sample size and power to replicate their results in theory
To be sure, we collaborated with @SanchoShimizu & @ChrisChiuLab to look in the UK Human SARS-CoV-2 challenge study.
3 of the 18 infected had a B*15:01 allele. All had symptoms. AND there is evidence that all were previously infected with OC43-CoV and HKU1-CoV.
Why this difference between our studies?
I am not sure. It might be linked to population stratification. HLA-B*15:01 is a common allele, and its frequencies varies a lot between populations in the US, but also within Europe.
=> important to really use genetic PCs in the test
Going back to HLA alleles and infectious diseases.
HLA is the main (or 1 of the main) association in studies that looked at chronic infections.
But it is essential for the acute phase. Example: there were no HLA associations in the first large GWAS for severe COVID-19.
I hope our work helps understand and clarify the role of HLA and memory T-cell immunity in the acute phase of a new infectious disease.
This was a huge team effort with many large consortiums involved. See all authors 👇 and link to the preprint: medrxiv.org/content/10.110…
Special thanks to Astrid Marchal for doing most of the work.
To @ETCirulli @kellyschiabor @my_helix @grzymski & Iva
To @AurelieCobat, @LaurentAbel4, @casanova_lab
To @SanchoShimizu @ChrisChiuLab
To @jacquesfellay (for teaching us everything on HLA and infectious diseases)
• • •
Missing some Tweet in this thread? You can try to
force a refresh
Co-circultation of both variants
20 samples with co-infections
Evidence of a few recombinations in co-infections
& 2 infections with 100% recombinant
Details in 🧵
@shishiluo@my_helix 2/
Recombination is one way a virus can evolve. It allows to 'test' a new combination of mutations, which could provide an advantage or not.
@shishiluo@my_helix@edwardcholmes@SimonLoriereLab 3/
Lots of talk about Delta-Omicron possible recombinations because in worse case scenario, it could be a bad combo. But also simply because
- it was likely to happen de to co-circulation of both
&
- also easier to identify because of high number of unique mutations of each
To try to 'predict' what may happen in the USA in next couple of weeks, we can look what was the BA.1.1 situation in these countries before BA.2 took over.
2/
Screening an entire population is different than doing the exome to identify cause of a rare disorder.
3/
The goal is to select gene <-> disease combinations that look like the one on the right in graph (Disease Z)
A large fraction of carriers (of a genetic variant) will present the disease if nothing is done
& strong enrichment in carriers compared to non-carriers.